Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma.

Mariana Sampaio Rodrigues de Lima Cristiane Aparecida Menezes de Pádua Paula Lana de Miranda Drummond Lívia Pena Silveira Jéssica Soares Malta Roberta Márcia Marques Dos Santos Adriano Max Moreira Reis

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)

Anticholinergic burden in MM patients is associated with lower scores in quality of life domains: global health and symptoms (QLQ-C30) and functional (QLQ-C30 and QLQ-MY20). The presence of polypharmacy is also associated with lower scores for functional scales and symptom scales (QLQ-C30).

Keyphrases

global health
end stage renal disease
multiple myeloma
public health
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
healthcare
adverse drug
emergency department
patient reported
electronic health record